Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a two part, Phase 1 open label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.

Study Design

The study is split into two phases, the dose escalation Phase and the Dose Expansion Phase.

The dose escalation has 2 parts: Part 1 is to assess the safety and tolerability of NUC-3373 administered weekly as an I.V. infusion on day 1, 8, 15, 22 of a 28-day cycle. Part 2 is assess the safety and tolerability of NUC-3373 administered fortnightly as an I.V. infusion on day 1, 15, of a 28-day cycle

The dose Expansion phase is to obtain a preliminary estimate of anti-tumor activity in specific tumour types as measured by response rate and duration of response and to further assess the safety profile of NUC-3373 administered over multiple cycles at the RP2D.

Study Population

Males or females with a histologically confirmed diagnosis of any solid tumour not amenable to standard therapy, refractory to standard therapy or for which no standard therapy exists will be eligible to enter the study provided they fulfil eligibility criteria.

Primary Objective

To establish the recommended phase 2 dose of NUC 3373.

Key Dates

January 2016 -  Opened to recruitment  

July 2017 – Expected study end date

Our team

  • Sarah Pearson

    OCTO Trial Management Director